MedCity News April 23, 2023
Frank Vinluan

The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.

Covid-19 sent the biotech industry into overdrive to develop vaccines that could tame the novel coronavirus. In relatively short order, and after different kinds of vaccines were researched, we have reached a state where the vast majority of U.S. vaccinations are messenger RNA shots. FDA guidance on booster shots for this fall is still developing, but the picture of what Covid-19 vaccines could look like in the years to come is already taking shape.

If...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
The risk of a bird flu pandemic is rising
Growing gulf in US life expectancy deepened by COVID-19 pandemic
Stick to the Science
Understanding the Growing Impact of Obesity in the United States
Wearable electrical nerve stimulation device eases long COVID pain and fatigue, say researchers

Share This Article